Lancashire and South Cumbria
Formulary
5 Infections
This chapter of the formulary has not been published, please use local guidelines.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here:
mlcsu.lscformulary@nhs.net
05-03-04 Influenza
Links
Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older) - Supply Disruption
Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
East Lancashire Primary Care: Antimicrobial guide primary care
East Lancashire Secondary Care: Antimicrobial guide secondary care
HPA guidance on use of antivirals (includes ordering information for IV zanamivir)
Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
NG199: Clostridioides difficile infection: antimicrobial prescribing
NHS England Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
NICE ES27: COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing
NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing
NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing
NICE NG191 COVID-19 rapid guideline: managing COVID-19
NICE NG191 COVID-19 rapid guideline: managing COVID-19
NICE NG224:Urinary tract infection in under 16s: diagnosis and management
NICE NG50: Cirrhosis in over 16s: assessment and management
NICE NG51: Sepsis: recognition, diagnosis and early management
NICE NG78: Cystic fibrosis: diagnosis and management
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
NICE TA732: Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
NICE TA900:Tixagevimab plus cilgavimab for preventing COVID-19
Oseltamivir changed concentration and dosing dispenser of oral suspension: MHRA update Oct 2012
Pandemic Flu drug information sources (UKMI)
Publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older).
UKMI Q&A: Can zanamivir be given to patients with renal impairment or patients on renal replacement therapies?
UKMI Q+A :Can mothers breastfeed after taking oseltamivir and zanamivir
UKMI Q+A :Can oseltamivir be taken by patients taking methotrexate?
West Lancashire Primary Care: Pan Mersey antimicrobial guide
Key
Full Site